TickerFacts.

Compare

Travere Therapeutics, Inc. vs Nature's Sunshine Products Inc vs BridgeBio Pharma, Inc. vs Zai Lab Ltd

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearTravere Therapeutics, Inc.
TVTX		Nature's Sunshine Products Inc
NATR		BridgeBio Pharma, Inc.
BBIO		Zai Lab Ltd
ZLAB
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$490.73M$480.14M$502.08M$457.18M
Revenue growth (YoY)+110.5%+5.7%+126.3%+15.0%
Gross marginn/a72.4%n/a58.3% (computed)
Operating margin-12.8%5.2%-104.2%-50.2%
Net margin-5.2%4.3%-146.0%-38.4%
Net income-$25.55M$20.45M-$732.94M-$175.54M
EPS (Diluted)-$0.29$1.06-$3.78-$0.16
Operating cash flow$37.78M$35.32M-$445.91M-$150.79M
Free cash flown/a$28.84M-$447.01M-$158.89M
Cash & equivalents$93.03M$93.89M$570.12M$679.57M
Total assets$605.19M$261.15M$936.02M$1.17B
Total liabilities$490.36M$99.59M$3.01B$456.88M
Shareholders' equity$114.83M$161.55M-$2.09B$715.50M
Return on year-end equity-22.2%12.7%n/a-24.5%
Shares outstanding90.92M17.51M194.77M1.11B

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearTravere Therapeutics, Inc.Nature's Sunshine Products IncBridgeBio Pharma, Inc.Zai Lab Ltd
Latest$490.73M
Ended 2025-12-31		$480.14M
Ended 2025-12-31		$502.08M
Ended 2025-12-31		$457.18M
Ended 2025-12-31
1 year earlier$233.18M
Ended 2024-12-31		$454.36M
Ended 2024-12-31		$221.90M
Ended 2024-12-31		$397.61M
Ended 2024-12-31
2 years earlier$145.24M
Ended 2023-12-31		$445.32M
Ended 2023-12-31		$9.30M
Ended 2023-12-31		$266.72M
Ended 2023-12-31
3 years earlier$109.46M
Ended 2022-12-31		$421.91M
Ended 2022-12-31		$77.65M
Ended 2022-12-31		$212.67M
Ended 2022-12-31
4 years earlier$131.84M
Ended 2021-12-31		$444.08M
Ended 2021-12-31		$69.72M
Ended 2021-12-31		$144.10M
Ended 2021-12-31